Orkambi ivacaftor/lumacaftor regulatory update

FDA approved an sNDA from Vertex for Orkambi ivacaftor/lumacaftor to treat cystic fibrosis (CF) in patients ages 6-11 who are homozygous for the F508del mutation in the CF transmembrane conductance re...